Regulation · Sport

Is GHK-Cu banned
in sport?

The answer turns on one list and one open-ended class. Here is what WADA’s Prohibited List names, what it does not, and who decides the rest, dated 18 November 2026.

Short answerRegulation · 6 min read · Updated 18 Nov 2026

The World Anti-Doping Agency’s Prohibited List does not name GHK-Cu in its 2026 or 2027 edition. That does not settle its status: class S0 covers pharmacological substances with no current government approval for human therapeutic use, and WADA says a peptide not named on the List “may still be prohibited”. Check with your anti-doping body.

Key takeaways

  • GHK-Cu, copper tripeptide-1 and prezatide do not appear on WADA’s 2026 Prohibited List or on the 2027 List, in force from 1 January 2027.
  • Class S0 prohibits, at all times, any pharmacological substance not addressed elsewhere on the List and with “no current approval by any governmental regulatory health authority for human therapeutic use”; the 2027 wording adds “peptides” to its examples, and WADA’s notes on the 2027 List say a peptide not specifically named “may still be prohibited”.
  • WADA names BPC-157 as an S0 example. It does not name GHK-Cu, and we draw no S0 conclusion about GHK-Cu: that is for WADA and anti-doping organisations.
  • Sport Integrity Australia names products containing GHK-Cu among its examples of unapproved peptide products, meaning goods not included in the Australian Register of Therapeutic Goods, and says “these unregulated peptides present a significant concern from both an anti-doping and public health perspective”.
  • Under the World Anti-Doping Code, athletes are responsible for any prohibited substance found in their samples, without any need to show intent.

01Is GHK-Cu on the WADA Prohibited List?

It is not named. We searched the full text of the World Anti-Doping Agency’s 2026 Prohibited List, and of the 2027 List that takes effect on 1 January 2027, for “GHK”, “copper”, “tripeptide” and “prezatide”. None appears, in any class or in either index (18 November 2026). Copper tripeptide-1 is GHK-Cu’s cosmetic ingredient name and prezatide copper is another name for it, so the search covered the names it is known by.

“Not named” is all the List itself says about GHK-Cu. The List is not a closed index: several classes list substances “including, but not limited to” the ones they name, and the first class, S0, is defined by approval status rather than by names. How a substance the List does not name is treated is decided by WADA and by anti-doping organisations. We do not make that call here, and this page takes no position on whether GHK-Cu is prohibited. For the wider picture: peptides and anti-doping.

02What does class S0 say, and what changed for 2027?

S0, “non-approved substances”, opens the List. It is prohibited at all times, in and out of competition, and every substance in it is a “Specified Substance”. The 2026 text reads:

“Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.”

The 2027 List keeps that sentence and adds one word to its examples: “designer drugs, peptides, substances approved only for veterinary use”. Both editions then say the class covers many substances “including but not limited to BPC-157” and three other examples. Neither edition names GHK-Cu.

WADA’s explanatory note on the 2027 List gives the reason for the new word: many peptides “not approved for human use by regulatory authorities” fall under S0 or under other classes, such as S2 or S4. Its next sentence reads: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.” Peptides are now named as examples “for clarity”. The note does not name GHK-Cu.

S0 turns on approval status in every country, not on a name. Working out whether any government regulator has approved a substance for human therapeutic use means checking every regulator, and we have not done that for GHK-Cu. So we draw no S0 conclusion about it. The neighbouring case is clearer: WADA names BPC-157 as an S0 example, so its status in sport is on the face of the List.

03Who decides how GHK-Cu is treated in sport?

WADA sets the List. The 2027 List describes itself as “a mandatory International Standard”, “updated annually following an extensive consultation process facilitated by WADA”. Under the World Anti-Doping Code (Article 4.3.3, worded the same in the 2021 edition now in force and in the 2027 edition that takes effect on 1 January 2027), WADA’s decision on which substances the List includes and how they are classified is final, and an athlete cannot challenge it by arguing, for example, that a substance lacks the potential to enhance performance.

Anti-doping organisations answer questions about specific substances. Global DRO, run by UK Anti-Doping, the US Anti-Doping Agency, Sport Integrity Canada and Swiss Sport Integrity, with Sport Integrity Australia among its licensees, gives information on whether specific medications are prohibited “based on the current World Anti-Doping Agency (WADA) Prohibited List”. It says it “does not contain information on, or that applies to, any dietary supplements”. Sport Integrity Australia’s peptides page gives an email address for questions about peptide products.

The Code puts responsibility on the athlete. Article 2.1.1, the same in both editions: “It is the Athletes’ personal duty to ensure that no Prohibited Substance enters their bodies.” Athletes are responsible for any prohibited substance found in their samples, and the Code says intent, fault, negligence or knowing use do not need to be shown.

04What have anti-doping bodies and regulators said about GHK-Cu?

Dated public statements we found that name GHK-Cu, with the two WADA Lists, checked on 18 November 2026.

DateWhoWhat it says about GHK-CuSource
1 Jan 2026WADA2026 Prohibited List in force. GHK-Cu, copper tripeptide-1 and prezatide are not named; BPC-157 is named in S0WADA 2026 List
13 Apr 2026TGA, Australia’s medicines regulatorNames GHK-Cu, with BPC-157, TB-500, retatrutide and CJC-1295, among examples of unapproved peptide products, “often supplied in injectable form”TGA safety advisory
Page current 22 Apr 2026FDA, USLists “GHK-Cu (for injectable routes of administration)” among withdrawn Category 2 compounding nominations: compounded injectable drugs containing it “may pose risk for immunogenicity”, with “limited data in humans”FDA compounding page
Between 11 May and 8 Jun 2026Sport Integrity AustraliaIts peptides page adds GHK-Cu to its examples of unapproved peptide products being promotedInternet Archive captures of the page
5 Nov 2026 (newest capture)Sport Integrity AustraliaStill names GHK-Cu, with melanotan II and retatrutide, among unapproved peptide products being promotedInternet Archive capture
1 Jan 2027WADA2027 Prohibited List takes effect. S0’s examples add “peptides”, named “for clarity”, WADA’s note says; GHK-Cu is not namedWADA 2027 List and explanatory note

Sport Integrity Australia names GHK-Cu on its peptides page. The page defines unapproved peptide products as goods not included in the Australian Register of Therapeutic Goods, and says they “can also be illegal and/or prohibited for use in sport”, that they are often sold as “research chemicals” or “not for human consumption”, and that “these unregulated peptides present a significant concern from both an anti-doping and public health perspective”; it then gives products containing GHK-Cu, melanotan II or retatrutide as examples of unapproved peptide products being promoted. We read the page on the Internet Archive, because the live site did not respond to our tools.

Medicines regulators in Australia and the US have named GHK-Cu, mainly in injectable products. Those are statements about medicines law, not anti-doping decisions. What they cover: GHK-Cu side effects and the GHK-Cu research guide.

05What we don’t know about GHK-Cu in sport

  • How WADA or a national anti-doping organisation would classify GHK-Cu. We found no published decision that names it.
  • Whether the form matters, for example a cosmetic containing copper tripeptide-1 against an injected product. We found no WADA document that addresses GHK-Cu in either form. How cosmetics with peptides are regulated: peptides in skincare.
  • Whether the List will name GHK-Cu in future. WADA revises it every year.
  • What Global DRO returns for GHK-Cu. Its search does not work with our tools, so we have not checked it.

Status changes are logged in our regulatory tracker.

This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.

RefSources

  1. World Anti-Doping Agency. The 2027 Prohibited List, World Anti-Doping Code International Standard (in force 1 Jan 2027): introduction, class S0, index. PDF 2027list_en_final_clean_4_nov_2026.pdf, downloaded and searched 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  2. World Anti-Doping Agency. The 2026 Prohibited List (in force 1 Jan 2026): class S0, S2.3, index. PDF 2026list_en_final_clean_september_2025.pdf, downloaded and searched 18 Nov 2026. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…
  3. World Anti-Doping Agency. World Anti-Doping Code 2021, Articles 2.1.1 (strict liability) and 4.3.3 (WADA’s determination of the List is final). Code, effective 1 Jan 2021; read 18 Nov 2026. www.wada-ama.org/sites/default/files/resources/files/2021_wa…
  4. World Anti-Doping Agency. World Anti-Doping Code 2027 (effective 1 Jan 2027), Articles 2.1.1 and 4.3.3, worded as in the 2021 Code. Code, October 2026 text; read 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-10/2027_world_anti…
  5. World Anti-Doping Agency. 2027 Prohibited List: summary of major modifications and explanatory notes (S0, non-approved substances). Undated (the file name carries 17 Aug 2026); read at wada-ama.org 18 Nov 2026. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…
  6. Sport Integrity Australia. Peptides explained (unapproved peptides; unapproved peptides in sport). Substance education page; the live site did not respond to our tools, read on the Internet Archive captures of 11 May, 8 Jun and 5 Nov 2026 (the newest), 18 Nov 2026. web.archive.org/web/20261105200754/https://www.sportintegrit…
  7. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 Apr 2026; read on the Internet Archive capture of 10 Aug 2026, the newest, 18 Nov 2026. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  8. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (GHK-Cu, for injectable routes of administration). Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  9. Global DRO (UK Anti-Doping, US Anti-Doping Agency, Sport Integrity Canada, Swiss Sport Integrity; licensees include Sport Integrity Australia). Home page: scope and supplements statement. Web page, read 18 Nov 2026. www.globaldro.com/Home
  10. PubChem. Prezatide copper, CID 71587328: synonyms include copper tripeptide-1 and GHK copper. Compound record, read 18 Nov 2026. pubchem.ncbi.nlm.nih.gov/compound/71587328

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is GHK-Cu on the WADA banned list?

It is not named on the 2026 Prohibited List or on the 2027 List, in force from 1 January 2027. Class S0 covers pharmacological substances with no current government approval for human therapeutic use, WADA says a peptide not named on the List “may still be prohibited”, and anti-doping organisations decide how it applies; check with your anti-doping body.

Is BPC-157 treated the same way as GHK-Cu?

No. WADA names BPC-157 as an example in class S0, non-approved substances, prohibited at all times, in both the 2026 and 2027 Lists. GHK-Cu is not named.

What did the 2027 List change for peptides?

The S0 sentence now includes “peptides” among its examples, alongside drugs in development, designer drugs and substances approved only for veterinary use. WADA’s note on the change says a peptide not specifically named on the List “may still be prohibited”. The List still names no copper peptide.

Has any anti-doping agency mentioned GHK-Cu?

Sport Integrity Australia’s peptides page names products containing GHK-Cu among its examples of unapproved peptide products, meaning goods not on Australia’s register of therapeutic goods, and says “these unregulated peptides present a significant concern from both an anti-doping and public health perspective”. Neither WADA List names it.

Who can say whether GHK-Cu is prohibited for a given athlete?

WADA sets the List, and the athlete’s anti-doping organisation applies it. Global DRO, run by several of those organisations, gives information on medications against the current List but not on supplements.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page